Thank you, Madam Chair.
Thank you to both presenters. You've certainly given us a different perspective on post-market surveillance today, talking about the gender issue and the issue with children and so on.
I find the gender-based analysis to be very interesting. I'm involved with a study on gender-based analysis and gender budgeting on another committee I sit on, so this is something that I find very pertinent. One of the things that is happening is that gender-based analysis for policies, programs, and risk management is already a part of the mandate of Health Canada. I think you're aware of that and I think you made some reference to that.
How would you build further on this mandate to ensure that post-market surveillance of these products captures the significant differences that could be there for different genders as well as different ages? Further to that, how would we get around some of the ethical issues that we've already alluded to here this morning regarding testing for young children or testing for pregnant women--those types of things?
Maybe you both could speak to those questions.